Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Cash-strapped Lotus Pharma Explains CapEx Decisions

publication date: Apr 25, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Lotus Pharmaceuticals (路坦制药有限公司) will be as much as six months late in completing its new Beijing facility, a combination of corporate headquarters, R&D labs, manufacturing, a crucial warehouse – and employee apartments. There is nothing particularly unusual about the delay of a construction project, even a major one. But Lotus is already on the outs with its shareholders. In 2008, the company allocated $33 million to building a warehouse in Outer Mongolia, some 200 miles from Beijing, then apparently abandoned the project to focus on an inside-Beijing center. After all the initiatives, Lotus ended 2010 with just $1.3 million in cash and two unfinished building projects. More details....

Stock Symbol: (OTCBB: LTUS)     Share this with colleagues:  

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners